Discover a groundbreaking webinar delving into how personalizing digital biomarkers and health protocols is crucial for harnessing the full potential of digital health technologies. Much of the discussion of personalized healthcare has involved using genomic information to adapt treatment. By providing a wealth of information about the individual patient, digital health technologies (DHTs) provide a similar opportunity. In fact, we believe that personalizing digital biomarkers and digital health protocols will be necessary to enable the effective use of digital health technologies. Recent work in the field has indicated huge benefits, including reducing the required sample size in a clinical trial by an order of magnitude and identifying the onset of illness before the patient is even aware of it.
However, this approach will require a paradigm shift in how data are analyzed, how clinical endpoints are formulated and how clinicians manage patients. New approaches will involve techniques from artificial intelligence (AI), machine learning and statistical process control.
Although the featured speakers will touch upon science and analytics, their focus will be on the practical implications of this paradigm shift for managers and executives — both in clinical research and in healthcare delivery. They will provide practical advice and lessons learned for managing these changes.
Join this webinar to gain insights into the practical paradigm shift in personalized healthcare with personalizing digital biomarkers and healthcare management.
Arthur Combs, MD, Medical Advisor
Dr. Arthur Combs is a Physician Executive with more than 20 years of experience in clinical practice and 20 more in the medical device industry. He has served as Executive VP of R&D for a Fortune 500 company and as CMO of four successful medical device start-up companies.
For the past seven years, Dr. Combs has focused his energies on the wearables/real-world data/digital biomarker space. Notably, he served as CMO of MC10, Inc., a wearable device and digital measures company from 2016 until their acquisition in 2020. He has been a lifelong contributor to the peer-reviewed literature including recent publications in Digital Biomarkers. He is a sought-after symposium presenter on the topic of The Clinical Imperative for Digital Biomarkers. Dr. Combs has extensive clinical research experience through collaborations with the pharmaceutical industry, academia and technology companies.
Dr. Stephen Smith, Co-Founder, ClearSky Medical Diagnostics
Stephen L. Smith, PhD is Co-founder and Director of ClearSky Medical Diagnostics Ltd. Incorporated in 2013, ClearSky markets a portfolio of CE Marked, clinically validated, medical devices that assist in the diagnosis and monitoring of patients with Parkinson’s disease and related conditions. Dr. Smith developed the underlying biologically inspired “white box” machine learning algorithms that power these devices to provide a quick, safe and reliable means of assessment, both in the hospital clinic and patients’ homes. Dr. Smith is also a Professor of Electronic Engineering at the University of York in the UK, a Fellow of the British Computer Society and a past Royal Academy of Engineering Enterprise Fellow.
Geoff Gill, CEO, Verisense Health
Geoff Gill is currently the Founder and CEO of Verisense Health, Inc. He has spent the last 15 years overseeing the acquisition and analysis of wearable sensor data, most recently as the President of Shimmer Americas, where he was responsible for Shimmer’s businesses in clinical trials and consumer neuroscience. Before Shimmer, he was the SVP of Operations at Innerscope Research, where he oversaw the conduct of approximately 700 consumer neuroscience studies involving over 100 thousand participants using wearable sensors. He has also led the development of blood gas and electrolyte sensors as VP of R&D at Bayer Diagnostics.
Who Should Attend?
This webinar will appeal to:
- Anyone interested in digital health technologies
- Pharmaceutical company executives involved in clinical trials with digital endpoints
- Researchers in digital health
- Providers and payers interested in how medicine will evolve
- People interested in the implications of regulatory change
What You Will Learn
Attendees will gain insights into:
- Why digital biomarkers need to be personalized
- What the benefits of this approach are
- How it differs from current practice
- Key practical lessons for implementation
Verisense Health, Inc. provides clinical data collection services through its Digital Health Panel and data from its Digital Biobank. Verisense Health is a spinoff of Shimmer Research, a leading manufacturer of wearable sensors for clinical, academic, and consumer research.